Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)


Hokkaido University \| Library \| HUSCAP	Advanced Search		言語

	Home
	About HUSCAP
	Open Access Policy

	Browse by Author

Browse
	Communities & Collections

	Scholarly Journals
	Theses
	Doctoral Dissertations Listed by Graduate Schools
	Conference Procs.
	Events

	HUSCAP Senior (in Japanese)

	Societies

	Downloads (country)

For university staff
	How to post your papers to HUSCAP
	Publication of theses
	Helpline about theses publication

Open Archives Compliant

You can search our collection also at:
	Google
	Google Scholar
	CiNii
	IRDB
	OAIster
	NDLTD

Files in This Item:

1-s2.0-S2213323217300488-main.pdf

1.12 MB

PDF

Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/68215

Title:	Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)
Authors:	Shiraishi, Hideaki Browse this author →KAKEN DB
	Egawa, Kiyoshi Browse this author
	Ito, Tomoshiro Browse this author
	Kawano, Osamu Browse this author
	Asahina, Naoko Browse this author
	Kohsaka, Shinobu Browse this author
Keywords:	Perampanel
	Dentatombral-pallidoluysian atrophy
	DRPLA
	Progressive myoclonic epilepsy
	Child
Issue Date:	2017
Publisher:	Elsevier
Journal Title:	Epilepsy & Behavior Case Reports
Volume:	8
Start Page:	44
End Page:	46
Publisher DOI:	10.1016/j.ebcr.2017.05.004
Abstract:	We administered perampanel (PER) to a bedridden 13-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA). The DRPLA diagnosis was based on the presence of a CAG trinucleotide repeat in the ATN1 gene. The patient experienced continuous myoclonic seizures and weekly generalized tonic-clonic seizures (GTCs). PER stopped the patient's myoclonic seizures and reduced the GTCs to fragmented clonic seizures. The patient recovered his intellectual abilities and began to walk again with assistance. We suggest that PER be considered as one of the key drugs used to treat patients with DRPLA.
Rights:	http://creativecommons.org/licenses/by-nc-nd/4.0/
Type:	article
URI:	http://hdl.handle.net/2115/68215
Appears in Collections:	北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 白石秀明

OAI-PMH ( junii2 , jpcoar_1.0 )

- Hokkaido University